Table of Content

Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
Chapter 4: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
Chapter 5: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
Chapter 6: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
Chapter 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
Chapter 8: COMPANY PROFILES
8.1. Abbott
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Bayer
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Biomark
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. LifeScan
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Menarini Diagnostics
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Nova Biomedical
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Nova Biomedtec
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Roche
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Siemens
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Trinity Biotech
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments



List of Figures

LIST OF FIGURES
FIGURE 01. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ABBOTT: NET SALES, 2020-2022*?($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. BAYER: NET SALES, 2020-2022*?($MILLION)
FIGURE 24. BAYER: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. BIOMARK: NET SALES, 2020-2022*?($MILLION)
FIGURE 27. BIOMARK: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. BIOMARK: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. LIFESCAN: NET SALES, 2020-2022*?($MILLION)
FIGURE 30. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. MENARINI DIAGNOSTICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 33. MENARINI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. MENARINI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. NOVA BIOMEDICAL: NET SALES, 2020-2022*?($MILLION)
FIGURE 36. NOVA BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. NOVA BIOMEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. NOVA BIOMEDTEC: NET SALES, 2020-2022*?($MILLION)
FIGURE 39. NOVA BIOMEDTEC: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. NOVA BIOMEDTEC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. ROCHE: NET SALES, 2020-2022*?($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. ROCHE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. SIEMENS: NET SALES, 2020-2022*?($MILLION)
FIGURE 45. SIEMENS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. SIEMENS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. TRINITY BIOTECH: NET SALES, 2020-2022*?($MILLION)
FIGURE 48. TRINITY BIOTECH: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. TRINITY BIOTECH: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ABBOTT: KEY EXECUTIVES
TABLE 05. ABBOTT: COMPANY SNAPSHOT
TABLE 06. ABBOTT: OPERATING SEGMENTS
TABLE 07. ABBOTT: PRODUCT PORTFOLIO
TABLE 08. ABBOTT: KEY STRATERGIES
TABLE 09. BAYER: KEY EXECUTIVES
TABLE 10. BAYER: COMPANY SNAPSHOT
TABLE 11. BAYER: OPERATING SEGMENTS
TABLE 12. BAYER: PRODUCT PORTFOLIO
TABLE 13. BAYER: KEY STRATERGIES
TABLE 14. BIOMARK: KEY EXECUTIVES
TABLE 15. BIOMARK: COMPANY SNAPSHOT
TABLE 16. BIOMARK: OPERATING SEGMENTS
TABLE 17. BIOMARK: PRODUCT PORTFOLIO
TABLE 18. BIOMARK: KEY STRATERGIES
TABLE 19. LIFESCAN: KEY EXECUTIVES
TABLE 20. LIFESCAN: COMPANY SNAPSHOT
TABLE 21. LIFESCAN: OPERATING SEGMENTS
TABLE 22. LIFESCAN: PRODUCT PORTFOLIO
TABLE 23. LIFESCAN: KEY STRATERGIES
TABLE 24. MENARINI DIAGNOSTICS: KEY EXECUTIVES
TABLE 25. MENARINI DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 26. MENARINI DIAGNOSTICS: OPERATING SEGMENTS
TABLE 27. MENARINI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 28. MENARINI DIAGNOSTICS: KEY STRATERGIES
TABLE 29. NOVA BIOMEDICAL: KEY EXECUTIVES
TABLE 30. NOVA BIOMEDICAL: COMPANY SNAPSHOT
TABLE 31. NOVA BIOMEDICAL: OPERATING SEGMENTS
TABLE 32. NOVA BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 33. NOVA BIOMEDICAL: KEY STRATERGIES
TABLE 34. NOVA BIOMEDTEC: KEY EXECUTIVES
TABLE 35. NOVA BIOMEDTEC: COMPANY SNAPSHOT
TABLE 36. NOVA BIOMEDTEC: OPERATING SEGMENTS
TABLE 37. NOVA BIOMEDTEC: PRODUCT PORTFOLIO
TABLE 38. NOVA BIOMEDTEC: KEY STRATERGIES
TABLE 39. ROCHE: KEY EXECUTIVES
TABLE 40. ROCHE: COMPANY SNAPSHOT
TABLE 41. ROCHE: OPERATING SEGMENTS
TABLE 42. ROCHE: PRODUCT PORTFOLIO
TABLE 43. ROCHE: KEY STRATERGIES
TABLE 44. SIEMENS: KEY EXECUTIVES
TABLE 45. SIEMENS: COMPANY SNAPSHOT
TABLE 46. SIEMENS: OPERATING SEGMENTS
TABLE 47. SIEMENS: PRODUCT PORTFOLIO
TABLE 48. SIEMENS: KEY STRATERGIES
TABLE 49. TRINITY BIOTECH: KEY EXECUTIVES
TABLE 50. TRINITY BIOTECH: COMPANY SNAPSHOT
TABLE 51. TRINITY BIOTECH: OPERATING SEGMENTS
TABLE 52. TRINITY BIOTECH: PRODUCT PORTFOLIO
TABLE 53. TRINITY BIOTECH: KEY STRATERGIES